Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies -





Published: March 2014 | Pages: 386 | Format: PDF

The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014.


Marketed antibodies are attractive for companies to create next generation variants and  biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules.


Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 75.7 bln in the year 2013. Cumulated 2013 sales of branded therapeutic antibodies approaching patent expiry and, therefore, target of biosimilar substitution, reached US$ 58.6 bln.

The report lists specifically for each target the branded products with their 2013 sales and up-side indications in development, as well as follower, biosuperior and biosimilar antibody drug candidates in development.
2013 Sales data are provided for

  • Rituxan/MabThera
  • Arzerra
  • Zevalin
  • Gazyva
  • Herceptin
  • Perjeta
  • Kadcyla
  • Avastin
  • Zaltrap
  • Erbitux
  • Vectibix
  • XGEVA
  • Yervoy
  • Adcetris
  • Poteligeo
  • Humira
  • Enbrel
  • Remicade
  • Simponi
  • Cimzia
  • Orencia
  • Nulojix
  • Ilaris
  • Arcalyst
  • Tysabri
  • Soliris
  • Xolair
  • Stelara
  • Actemra/RoActemra
  • Benlysta
  • Lemtrada
  • ReoPro
  • Nplate
  • Prolia
  • Lucentis
  • Eylea
  • Synagis

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:

  • CD20
  • Her2
  • VEGF
  • TNF
  • EGF-R
  • CD52
  • GPIIb/IIIa
  • B7.1/B7.2 (CD80/CD86)
  • IL-6R
  • Alpha4/beta1/7 integrin
  • IgE
  • RSV
  • RANKL
  • Complement C5
  • IL-12/IL-23

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents 

1. 2013 Sales of Recombinant Therapeutic Antibodies 

  • Overview and Summary of Antibody Sales 2013
  • Cancer Antibody Sales 2013
  • Inflammatory and Autoimmune Antibody Sales 2013
  • Cardiohematometabolic Antibody Sales 2013
  • Ophthalmic Antibody Sales 2013
  • Antiviral Antiody Sales 2013

2. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors 

  • Marketed CD20 Antibodies & Sales
    -           Rituxan/MabThera Pipeline & Sales
    -           Arzerra Pipeline & Sales
    -           Gazyva Pipeline & Sales
    -           Bexxar & Zevalin Pipeline & Sales
  • Biosuperior CD20 Antibodies
  • Biosimilar CD20 Antibodies
    -           Rituxan/MabThera (rituximab) Biosimilars
    -           Arzerra (ofatumumab) Biosimilars

3. Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors 

  • Marketed Her2 Antibodies
    -           Herceptin Sales & Pipeline
    -           Perjeta Sales & Pipeline
    -           Kadcyla Sales & Pipeline
  • Trastuzumab Biobetters/Biosuperiors
    -           Engineered Her2 Antibodies
    -           Bi- and Multispecific Her2 Antibodies
    -           Her2 Antibody-Drug Conjugates
    -           Her2 Imaging Antibodies
  • Trastuzumab Biosimilars

4. VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors 

4a. Bevacizumab Biosimilars and Biosuperiors 

  • Marketed VEGF Antibodies
    -           Avastin Sales & Pipeline
    -           Zaltrap Sales & Pipeline
  • “Next Generation Avastin” Pipeline
    -           Anti-VEGF Antibody Pipeline
    -           Anti-VEGF-Receptor Antibody Pipeline
    -           Bispecific Anti-VEGF Antibody Pipeline
  • Avastin Biosimilar Pipeline

4b. Ranibizumab Biosimilars and Biosuperiors 

  • Marketed VEGF Antibody
    -           Lucentis Sales & Pipeline
    -           Eylea Sales & Pipeline
  • “Next Generation Lucentis” Pipeline
  • Lucentis Biosimilar Pipeline

5. EGF-R Antibodies –Biosimilars and Biosuperiors 

  • Marketed EGF-R Antibodies
    -           Erbitux Sales & Pipeline
    -           Vectibix Sales & Pipeline
    -           Nimotuzumab Pipeline
  • EGF-R Antibody Biobetters/Biosuperiors
    -           Engineered EGF-R Antibodies
    -           Bi- and Multispecific EGF-R Antibodies
    -           EGF-R Antibody-Drug Conjugates
  • EGF-R Antibody Biosimilars
    -           Cetuximab Biosimilars
    -           Panitumumab Biosimilars

6. TNF Antibodies –Biosimilars and Biosuperiors 

  • Marketed TNF Antibodies
    -           Humira Sales & Pipeline
    -           Remicade Sales & Pipeline
    -           Enbrel Sales & Pipeline
    -           Simponi Sales & Pipeline
    -           Cimzia Sales & Pipeline
  • Biosuperior / Biobetter TNF Antibodies
  • Biosimilar TNF Antibodies
    -           Humira Biosimilar Antibody Pipeline
    -           Remicade Biosimilar Antibody Pipeline
    -           Enbrel Biosimilar Antibody Pipeline
    -           Simponi Biosimilar Antibody Pipeline
    -           Cimzia Biosimilar Antibody Pipeline

7. IgE Antibodies: Xolair, Biosuperiors & Biosimilars
Marketed IgE Antibody Sales & Pipeline
Biosuperior IgE Antibodies
Biosimilar IgE Antibodies

8. Interleukin-6 Receptor (IL-6R) Antibodies: Actemra, Biosuperiors & Biosimilars
Marketed Il-6R Antibody Sales & Pipeline
Biosuperior IL-6(R) Antibodies
Biosimilar IL-6(R) Antibodies

9. GPIIb/IIIa Antibodies: ReoPro, Biosuperios & Biosimilars
Marketed GPIIb/IIIa Antibody Sales & Pipeline
Biosimilar GPIIb/IIIa Antibodies

10. CD52 Antibodies: Lemtrada, Biosuperios & Biosimilars
Marketed CD52 Antibody Sales & Pipeline
Biosimilar CD52 Antibodies

11. Apha4/beta1/7 Antibodies: Tysabri, Biosuperiors & Biosimilars
Marketed Alpha4/beta1/7 Antibody Sales & Pipeline
Biosimilar Alpha4/beta1/7 Antibodies

12. Complement C5 Antibodies: Soliris, Biosuperiors & Biosimilars
Marketed C5 Antibody Sales & Pipeline
Biosuperior C5 Antibodies
Biosimilar C5 Antibodies

13. Respiratory Syncytial Virus (RSV): Synagis, Biosuperiors & Biosimilars
RSV Antibody Sales & Pipeline
Biosuperior RSV Antibodies
Biosimilar RSV Antibodies

14. RANKL Antibodies: Prolia/XGEVA, Biosuperiors & Biosimilars
Marketed RANKL Antibody Sales & Pipeline
Biosuperior RANKL Antibodies

15. CD80/86 (B7-1/B7-2) Antibodies: Orencia; Nulojix, Biosuperiors & Biosimilars
CD80/86 Antibody Sales & Pipeline
Biosuperior CD80/86 Antibodies
Biosimilar CD80/86 Antibodies

16. Interleukin-12/-23 Antibodies: Stelara, Biosuperiors & Biosimilars
Marketed IL-12/-23 Antibody Sales & Pipeline
Biosimilar IL-12/-23 Antibodies

17.  Corporate  Biosimilar and Biosuperior Therapeutic Antibody Pipelines